

MI-3454

Chemical Properties


CAS No. : 2134169-43-8

Formula: C32H35F3N8OS

Molecular Weight: 636.73

Storage: Store at low temperature, Store under nitrogen
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation. MI-3454 induces complete remission or regression of leukemia in a mouse model of leukemia with MLL1 rearrangement or NPM1 mutation through the down-regulation of key genes involved in leukemogenesis. complete remission or remission.
Targets(IC50)	Epigenetic Reader Domain, Histone Methyltransferase
In vitro	In murine bone marrow cells transformed with MLL-AF9 or Hoxa9/Meis1, MI-3454 (0.001, 0.01, 0.1, 1, 10 μM; 7 days) demonstrated a significant reduction in cell proliferation[1].
In vivo	In 8- to 10-week-old female NSG mice (MV-4-11 xenotransplantation model of MLL leukemia), MI-3454 (120 mg/kg; orally; once or twice daily for 7 consecutive days) is sufficient to block leukemia progression[1].

Solubility Information

Solubility	DMSO: 20 mg/mL (31.41 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5705 mL	7.8526 mL	15.7052 mL
5 mM	0.3141 mL	1.5705 mL	3.141 mL
10 mM	0.1571 mL	0.7853 mL	1.5705 mL
50 mM	0.0314 mL	0.1571 mL	0.3141 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Szymon Klossowski, et al. Menin Inhibitor MI-3454 Induces Remission in MLL1 -rearranged and NPM1 -mutated Models of Leukemia. J Clin Invest. 2020 Feb 3;130(2):981-997.

Wu J, Qin C, et al. Epigenetic drug screening for trophoblast syncytialization reveals a novel role for MLL1 in regulating fetoplacental growth. BMC Med. 2024 Feb 5;22(1):57.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481